Inventor · disambiguated record
John S. Tokarski
Also filed as: TOKARSKI JOHN · TOKARSKI JOHN S
37 granted patents·10 pending applications·389 citations·filing 2000–2025
97Inventor score
Top patents by PatentIndex Score
47 records- 0197US9505748B2Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responsesBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Nov 29, 2016·53 cites·9 claims
- 0297US9458156B2Tricyclic compounds as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Oct 4, 2016·25 cites·3 claims
- 0396US10000480B2Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responsesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 19, 2018·20 cites·14 claims
- 0496US7723336B2Fused heterocyclic compounds useful as kinase modulatorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted May 25, 2010·50 cites·16 claims
- 0595US11021462B2Sulfone pyridine alkyl amide-substituted heteroaryl compoundsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 1, 2021·6 cites·28 claims
- 0694US11787779B2Sulfone pyridine alkyl amide-substituted heteroaryl compoundsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Oct 17, 2023·2 cites·4 claims
- 0794USRE47929EAmide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responsesBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Apr 7, 2020·19 cites·39 claims
- 0894US9273057B2Imidazotriazinecarbonitriles useful as kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Mar 1, 2016·29 cites·15 claims
- 0992US9663467B2Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responsesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted May 30, 2017·21 cites·7 claims
- 1092US6653304B2Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseasesBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 25, 2003·62 cites·8 claims
- 1190US9987266B2Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responsesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jun 5, 2018·9 cites·1 claims
- 1289US7297695B2Pyrrolotriazine compounds as kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Nov 20, 2007·9 cites·4 claims
- 1388US10669272B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 2, 2020·4 cites·13 claims
- 1488US9315494B2Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responsesBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Apr 19, 2016·14 cites·11 claims
- 1587US9540333B2Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNαBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 10, 2017·11 cites·16 claims
- 1687US7547782B2Met kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Jun 16, 2009·6 cites·17 claims
- 1787US2025243193A1Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responsesBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1886US12365667B2Sulfone pyridine alkyl amide-substituted heteroaryl compoundsBRISTOL MYERS SQUIBB CO·Filed 2023·Granted Jul 22, 2025·0 cites·13 claims
- 1983US2025304555A1Sulfone pyridine alkyl amide-substituted heteroaryl compoundsBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 2081US7417040B2Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3BRISTOL MYERS SQUIBB CO·Filed 2005·Granted Aug 26, 2008·3 cites·13 claims
- 2179US10273237B2Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responsesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Apr 30, 2019·4 cites·2 claims
- 2279US9492460B2Carbazole compounds useful as bromodomain inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Nov 15, 2016·4 cites·15 claims
- 2379US7880004B2Met kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Feb 1, 2011·4 cites·16 claims
- 2478US10053454B2Carbazole compounds useful as bromodomain inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Aug 21, 2018·3 cites·5 claims
- 2578US7378426B2Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3BRISTOL MYERS SQUIBB CO·Filed 2005·Granted May 27, 2008·2 cites·30 claims
- 2678US7141571B2Pyrrolotriazine compounds as kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Nov 28, 2006·8 cites·4 claims
- 2777US6795776B1Crystallographic structure of the androgen receptor ligand binding domainBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Sep 21, 2004·12 cites·3 claims
- 2876US7846931B2Pyrrolotriazine compounds as kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Dec 7, 2010·1 cites·1 claims
- 2976US2022356180A1Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responsesBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 3074US9751879B2Tricyclic compounds as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Sep 5, 2017·1 cites·13 claims
- 3173US7084160B2Heterocyclic inhibitors of kinasesBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Aug 1, 2006·6 cites·4 claims
- 3267US11713316B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Aug 1, 2023·0 cites·11 claims
- 3364US10112941B2Tricyclic compounds as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Oct 30, 2018·0 cites·3 claims
- 3464US9221826B2Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseasesWROBLESKI STEPHEN T·Filed 2012·Granted Dec 29, 2015·1 cites·10 claims
- 3563US2025084056A1Substituted oxoisoindolinyl piperidine-2,6-dione compoundsBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 3661US10954238B1Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Mar 23, 2021·0 cites·11 claims
- 3756US7547711B2Heterocyclic inhibitors of kinasesBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Jun 16, 2009·0 cites·2 claims
- 3854US2011039838A1Pyrrolotriazine compounds as kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2010·Application pending·0 cites
- 3953US2016108050A1Imidazotriazinecarbonitriles useful as kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 4051US7225083B2Crystallographic structure of the androgen receptor ligand binding domainBRISTOL MYERS SQUIBB CO·Filed 2004·Granted May 29, 2007·0 cites·8 claims
- 4151US2010029676A1T315a and f317i mutations of bcr-abl kinase domainSAWYERS CHARLES L·Filed 2006·Application pending·0 cites
- 4251US2023089255A1Combinations of dgk inhibitors and checkpoint antagonistsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 4348US10196387B2Carbazole compounds useful as bromodomain inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Feb 5, 2019·0 cites·5 claims
- 4446US2016318928A1Tricyclic compounds as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 4545US2007078136A1Fused heterocyclic compounds useful as kinase modulatorsBRISTOL MYERS SQUIBB CO·Filed 2006·Application pending·0 cites
- 4644US12037323B2Uracil derivatives as Mer-AXL inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jul 16, 2024·0 cites·10 claims
- 4738US8921368B2Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseasesWROBLESKI STEPHEN T·Filed 2012·Granted Dec 30, 2014·0 cites·9 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →